Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05272241 · ClinicalTrials.gov registry record
Registry of Asthma Characterization and Recruitment 3 (RACR3)
A clinical trial of Asthma, sponsored by National Institute of Allergy and Infectious Diseases (NIAID).
- Recruiting
- Registry status
- 1,500
- Enrollment target
- 7
- Study locations
NCT05272241: Recruiting study of Asthma, sponsored by National Institute of Allergy and Infectious Diseases (NIAID).
NCT05272241 is a study of Asthma that is actively recruiting participants, run by National Institute of Allergy and Infectious Diseases (NIAID). The registered enrollment target is 1,500 participants, roughly in line with the 1,559-participant average among 374 other Asthma trials with a reported enrollment target. The trial reports 7 study locations across 6 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT05272241, a study of Asthma, is actively recruiting participants, sponsored by National Institute of Allergy and Infectious Diseases (NIAID).
- RECRUITING
- Registry status
- 1,500 participants
- Enrollment target
- 7
- Study locations
Study Summary
This is a multi-center, non-interventional registry to create and maintain a database of participants to serve as a recruitment source for current and future DAIT NIAID-sponsored Childhood Asthma in Urban Settings (CAUSE) studies.
Primary Outcome
Characteristics of the participants enrolled in the registry will be assessed on a periodic basis (descriptive summary of diagnosis and parameters associated with the former).
Conditions Studied
Study Locations (7)
New York
- Icahn School of Medicine at Mount Sinai: Division of Clinical Immunology, Immunology Institute - New York
- Columbia University Medical Center: Department of Medicine, Division of Pulmonary, Allergy and Critical Care Medicine - New York
Colorado
- Children's Hospital Colorado: Allergy Program - Aurora
District of Columbia
- Children's National Medical Center: Inner City Asthma Consortium (ICAC) Clinical Research Site - Washington D.C.
Illinois
- Ann & Robert H. Lurie Children's Hospital of Chicago: Division of Allergy and Immunology - Chicago
Massachusetts
- Boston Children's Hospital: Department of Immunology - Boston
Ohio
- Cincinnati Children's Hospital Medical Center: Asthma Center - Cincinnati
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 1,500 participants |
| Start Date | 2022-04-15 |
| Est. Completion | 2028-05 |
What NCT05272241 shows while recruiting
NCT05272241 is an observational study that tracks outcomes without assigning an intervention. Its 1,500 participants enrollment target places it among the larger protocols in the corpus, roughly in line with the 1,559-participant average among 374 other Asthma trials with a reported enrollment target.
The record links to 1 condition, with Asthma appearing as the primary indexed condition, and to 0 interventions.
NCT05272241 lists 7 locations in 6 states (New York, Colorado, District of Columbia).
Frequently Asked Questions
What is clinical trial NCT05272241 about?
NCT05272241 is a clinical study titled "Registry of Asthma Characterization and Recruitment 3 (RACR3)". This is a multi-center, non-interventional registry to create and maintain a database of participants to serve as a recruitment source for current and future DAIT NIAID-sponsored Childhood Asthma in Urban Settings (CAUSE) studies.
What is the current status of trial NCT05272241?
This trial is currently recruiting. The enrollment target is 1,500 participants. The study started on 2022-04-15. Estimated completion is 2028-05.
What conditions does trial NCT05272241 study?
This clinical trial studies the following conditions: Asthma.
Who is sponsoring clinical trial NCT05272241?
This trial is sponsored by National Institute of Allergy and Infectious Diseases (NIAID), which has 2,006 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT05272241 being conducted?
This trial has 7 study locations across Colorado, District of Columbia, Illinois, Massachusetts, New York. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Asthma
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT05272241's enrollment target sits among peer trials
1,500 27th of 374 higher than 348 of 374 other Asthma trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Asthma trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Innate Immunity in Allergic Asthma
RECRUITING
-
Automated Inhaler Monitoring for Asthma Medication Usage
RECRUITING · NA
-
Impact of Metabolic Dysfunction and Mucus Plugging on Asthma Physiology
RECRUITING
-
Depemokimab Asthma Imaging and Bronchoscopy Sub-Study
RECRUITING · Phase 3
-
Escitalopram in Asthma Patients With Frequent Exacerbation
RECRUITING · Phase 2
-
Measuring the Effect of Dupilumab Treatment on Mucociliary Clearance (MCC) in Subjects With Moderate to Severe Asthma
RECRUITING · Phase 4
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT00178724 · 1,500 participants
Spinal Cord Injury Registry - North American Clinical Trials Network
- NCT00951366 · 1,500 participants
Preterm Lung Patient Registry
- NCT01050504 · 1,500 participants
Collecting and Studying Blood and Tissue Samples From Patients With Locally Recurrent or Metastatic Prostate or Bladder/Urothelial Cancer
- NCT02071134 · 1,500 participants
Registry of Deep Brain Stimulation With the VERCISE™ System: Vercise DBS Registry
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI